AzTrials
AzTrials

Post Induction HypotensionNCT07022730

Prophylactic Noradrenaline Infusion and Its Impact on Post-induction Hypotension

A study testing Noradrenaline 0.2 mcg/kg/min at 5 minutes before induction in people with Post Induction Hypotension and Sepsis, run by Cairo University at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

researchers aim to evaluate the influence of prophylactic noradrenaline infusion on post-induction hypotension Read more about this study

Who is it for?
Ages 20 to 65 years
Conditions the study is for
Post Induction Hypotension, Sepsis
What is being tested?
Noradrenaline 0.2 mcg/kg/min at 5 minutes before induction
Could I receive a placebo?
No, everyone receives an active treatment
How many people
80 participants
Where
1 siteEgypt
Study dates
22 Jun 2025to 17 Sep 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adult patients with sepsis undergoing source control surgery.

Who cannot join

  • Patient refusal
  • Patient with cardiac pathology ( ischemic heart disease or heart failure)
  • Preoperative hemodynamic instability (defined as MAP < 65 mmHg)
  • Rapid sequence induction

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Cairo University

    Cairo, Cairo Governorate, 6890

Other trials in Egypt

About this study

Official title: The Novel Use of Prophylactic Noradrenaline Infusion and Its Impact on Post-induction Hypotension in Patients With Surgical Sepsis, a Double Blind Randomized Controlled Trial

researchers aim to evaluate the influence of prophylactic noradrenaline infusion on post-induction hypotension

Read the detailed description

If post-induction hypotension is not addressed promptly, it can lead to severe complications such as reduced blood flow, acute kidney damage, and myocardial ischemia. As a result, early detection and proactive intervention are crucial. Researchers of the current study decided to investigate impact of noradrenaline administered as a prophylaxis on post induction hypotension

Being tested
Noradrenaline 0.2 mcg/kg/min at 5 minutes before induction
Keywords
Hypotension, noradrenaline, sepsis
Medical subject headings
Sepsis, Hypotension

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Noradrenaline 0.2 mcg/kg/min at 5 minutes before inductionDrug

    noradrenaline will be given at a rate of 0.2 mcg/kg/min that will start 5 minutes before induction

Study groups in NCT07022730
Study groupRoleWhat they receive
NoradrenalineActive comparatorNoradrenaline will be infused at a fixed rate of 0.2 mic/kg/min at 5 minutes before induction
Receives: Drug: Noradrenaline 0.2 mcg/kg/min at 5 minutes before induction
ControlNo interventionPatients will receive normal saline

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Incidence of post induction hypotension in both groups

    Hypotension will be considered if MAP< 65 mmHg

    Measured: Within the first 10 minutes of induction.

Secondary outcomes (3)
  1. Incidence of acute kidney injury

    defined as the highest postoperative value > 1.5-fold or 0.3 mg/dL greater than the preoperative value

    Measured: 7 days post operative

  2. Incidence of myocardial infarction

    defined as a peak troponin T value exceeding 15 times the normal upper limit, along with new pathological Q waves, ST elevation or depression, and hyperacute T wave on ECG and symptoms suggestive of myocardial infarction

    Measured: 7 days postoperative

  3. Incidence of stroke

    clinical or image finding of stroke

    Measured: 7 days postoperative

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Jun 2025
  2. Study start22 Jun 2025
  3. Primary completion17 Sep 2025
  4. Study completion17 Sep 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
80 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07022730
Sponsor's protocol ID
noradrenaline and PIH
Status last verified
Sep 2025
First submitted
7 Jun 2025
Last updated
18 Sep 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: IPD may not be shared due to privacy concerns, regulatory restrictions, and informed consent limitations.

Publications

  • Goertz AW, Lindner KH, Seefelder C, Schirmer U, Beyer M, Georgieff M. Effect of phenylephrine bolus administration on global left ventricular function in patients with coronary artery disease and patients with valvular aortic stenosis. Anesthesiology. 1993 May;78(5):834-41. doi: 10.1097/00000542-199305000-00005.

    PubMed 8489054
  • Czajka S, Putowski Z, Krzych LJ. Post-induction hypotension and intraoperative hypotension as potential separate risk factors for the adverse outcome: a cohort study. J Anesth. 2023 Jun;37(3):442-450. doi: 10.1007/s00540-023-03191-7. Epub 2023 Apr 21.

    PubMed 37083989
  • Tangkulpanich P, Angkoontassaneeyarat C, Trainarongsakul T, Jenpanitpong C. Factors Associated with Postintubation Hypotension Among Patients with Suspected Sepsis in Emergency Department. Open Access Emerg Med. 2023 Nov 14;15:427-436. doi: 10.2147/OAEM.S426822. eCollection 2023.

    PubMed 38022743
  • Helmy MA, Mostafa MS, Saber AT, Ali MA, Ismail IA, Naguib BA, Elaraby MM, Milad LM. Preemptive noradrenaline infusion: a game-changer against post-induction hypotension in surgical sepsis: a randomized double blind trial. BMC Anesthesiol. 2026 Apr 11;26(1):236. doi: 10.1186/s12871-026-03783-2.

    PubMed 41965525

Questions about this trial

What is this clinical trial studying?

A study testing Noradrenaline 0.2 mcg/kg/min at 5 minutes before induction in people with Post Induction Hypotension and Sepsis, run by Cairo University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Incidence of post induction hypotension in both groups (time frame: Within the first 10 minutes of induction.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07022730, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Sep 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in